Walleye Capital
GSK icon

Walleye Capital’s GSK GSK Stock Holding History

Walleye Capital’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.3M Sell
150,300
-100,600
-40% -$5.45M 0.03% 490
2025
Q4 		$12.3M Buy
250,900
+145,900
+139% +$6.8M 0.04% 515
2025
Q3 		$4.53M Buy
105,000
+88,900
+552% +$3.47M 0.02% 984
2025
Q2 		$618K Sell
16,100
-2,500
-13% -$95.5K ﹤0.01% 2465
2025
Q1 		$721K Sell
18,600
-136,100
-88% -$4.98M ﹤0.01% 2259
2024
Q4 		$5.23M Sell
154,700
-62,800
-29% -$2.26M 0.01% 1040
2024
Q3 		$8.89M Buy
217,500
+55,800
+35% +$2.28M 0.02% 763
2024
Q2 		$6.23M Sell
161,700
-60,700
-27% -$2.55M 0.01% 1126
2024
Q1 		$9.53M Buy
222,400
+168,900
+316% +$6.97M 0.02% 853
2023
Q4 		$1.98M Sell
53,500
-300
-0.6% -$10.8K ﹤0.01% 1785
2023
Q3 		$1.95M Sell
53,800
-11,600
-18% -$412K 0.01% 1755
2023
Q2 		$2.33M Buy
65,400
+35,900
+122% +$1.29M 0.01% 1231
2023
Q1 		$1.05M Buy
+29,500
New +$1.03M 0.02% 1138
2022
Q4 		– Sell
-19,800
Closed -$583K – 3357
2022
Q3 		$583K Buy
+19,800
New +$750K 0.01% 1357

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Walleye Capital's GSK Position: Q1 2026 in Review

Walleye Capital increased its GSK (GSK) stake by 619% in Q1 2026, buying an estimated $17.4M and bringing the position to 373,096 shares worth $20.6M. The position accounts for 0.09% of the portfolio, ranked #187.

Walleye Capital first reported a position in GSK in Q3 2018 and has held it in 11 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Walleye Capital held 373,096 shares of GSK worth $20.6M as of Q1 2026.
  • Walleye Capital bought 321,192 GSK shares in Q1 2026, an estimated $17.4M.
  • GSK made up 0.09% of Walleye Capital's portfolio in Q1 2026, its #187 holding.
  • Walleye Capital first reported a position in GSK in Q3 2018 and has held it in 11 quarters since.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.